Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.
Clarient has filed a registration statement with the Securities and Exchange Commission on Form S-3 relating to shares of Clarient owned by Safeguard.
Clarient has launched a new gene mutation test to help physicians select the appropriate therapy for non-small cell lung cancer.
Safeguard Scientifics Inc. has received $19.5 million in cash, and freed up another $12.3 million in cash due to one of its portfolio companies completing the second part of a private placement of convertible preferred stock.
Clarient is launching a new breast cancer test that helps physicians assess the probability of a patient’s cancer returning.